
































Myeloid-associated immunoglobulin-like receptor (MAIR)-I is expressed on most myeloid lineage cells 
and regulates the activation of these cells. Here we showed that decreased mortality in 
MAIR-I–deficient mice with experimental peritonitis-sepsis. Because sepsis is the systemic inflammatory 
syndrome induced by severe infections, remains a leading cause of death worldwide, these results suggest 
that MAIR-I is a novel molecular target for the treatment of sepsis. 
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MAIR (myeloid associated Ig like 
receptors)を同定した(Yotsumoto K, et al. J 
Exp Med. 2003)。MAIR 分子群はマウス染色体





られる(Nakahashi et al, J Immunol.2007, 
Nakano et al, Mol Immunol.2008, Can et al, 






制性レセプターであること(Okoshi et al, 
Int Immunol.2004)を明らかとした。 
 























































































































〔学会発表〕（計 1 件） 
1.小田ちぐさ 
A novel therapeutic approach for sepsis 
using a monoclonal antibody against 
MAIR-I (CD300a) 
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